#1 Clinical Trials Search in Europe

Study of CART84 Treatment for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

2 1 1

What is this study about?

This study focuses on treating patients with Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia (T-ALL) that have not responded to previous treatments or have returned after treatment. The study will test a new treatment called CART84, which is made from a patient’s own immune cells that are modified in a laboratory to better fight cancer cells.

The purpose of this research is to determine if CART84 is safe to use and to find the most effective dose for treating these types of blood cancers. The treatment involves collecting immune cells from the patient, modifying them to target cancer cells, and then returning them to the patient through an intravascular infusion (delivery into a vein).

During the study, patients will receive the CART84 treatment and will be monitored for response to therapy and any side effects. After receiving CART84, some patients may proceed to receive a stem cell transplant from a matched donor. The study includes regular blood tests and bone marrow examinations to check how well the treatment is working.

1 Initial medical assessment

Your blood and bone marrow will be tested to confirm at least 5% of leukemia cells are present

Medical tests will check your kidney, liver, lung, and heart function

Your blood oxygen level must be above 92% when breathing room air

Your physical condition will be evaluated using the ECOG scale, which measures your ability to perform daily activities

2 Pre-treatment preparation

A stem cell donor will be identified for possible future transplant

The donor can be a family member or unrelated person with matching tissue type

This transplant may occur between 30-90 days after your CART84 treatment

3 CART84 treatment

You will receive CART84 cells through an intravenous infusion

The treatment is given as a dispersion (liquid form) into your bloodstream

Your response to the treatment will be monitored closely for the first 30 days

4 Post-treatment monitoring

Regular blood tests will track your recovery and the presence of CART84 cells

Bone marrow tests will check for remaining cancer cells

Your blood cell counts will be monitored to ensure proper recovery

You will be checked for possible side effects for up to 6 months

5 Long-term follow-up

Your progress will be monitored for up to 24 months

Regular checkups will assess your overall health and cancer status

If needed, you may proceed to stem cell transplant between 30-90 days after CART84 treatment

Who Can Join the Study?

  • Must be 18 years or older at the time of signing the consent
  • Male participants must use 2 methods of contraception (one barrier method by the patient and one highly effective method by their partner) during treatment and for 12 months after the last dose
  • Must have adequate organ function including:
    – Normal or slightly elevated liver function tests
    – Good kidney function
    – Normal bilirubin levels (except for patients with Gilbert’s syndrome)
    – Heart pumping function of at least 45%
    – Blood oxygen levels above 92% when breathing room air
  • Must be willing and able to provide written informed consent
  • Must have good physical function status (ECOG score of 0 or 1, meaning able to carry out light work)
  • Must have diagnosed blood cancer (AML or T-ALL) with at least 5% cancer cells in bone marrow or blood, and either:
    – Disease that didn’t respond to initial treatment
    – Second or later relapse
    – Disease that returned and didn’t respond to salvage therapy
    – Disease that returned after stem cell transplant (at least 3 months must have passed)
  • Must have confirmed CD84 protein present on cancer cells
  • For T-ALL patients: must have specific type of T-ALL (either lacking CD4 and CD8 markers, or having these markers but no cancer cells in blood)
  • Must have an available stem cell donor (family member or unrelated) for possible transplant 30-90 days after treatment
  • Women who can become pregnant must have a negative pregnancy test before starting treatment
  • Women who are not post-menopausal or surgically sterile must use 2 methods of contraception (one highly effective method plus a barrier method) during treatment and for 12 months after the last dose

Who Cannot Join the Study?

  • Active or uncontrolled infection, including patients with hepatitis B, hepatitis C, or HIV (human immunodeficiency virus)
  • History of other cancers in the past 3 years, except for successfully treated non-melanoma skin cancer or cervical cancer in situ
  • Pregnant or breastfeeding women
  • Severe heart problems, including uncontrolled heart failure or serious heart rhythm disorders
  • Severe lung problems that require oxygen therapy
  • Severe kidney problems requiring dialysis
  • Severe liver problems
  • Active disease in the central nervous system (brain and spinal cord)
  • Previous treatment with CAR-T cell therapy
  • Participation in another clinical trial within 30 days before starting this study
  • Any condition that, in the opinion of the study doctor, would make participation unsafe
  • Unable to provide informed consent
  • Known allergic reactions to components of the study treatment
  • Psychiatric conditions that could interfere with study participation

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario Y Politecnico La Fe Valencia Spain

Other Sites

Site Name City Country Status
Hospital Clinic De Barcelona Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Recruiting
09.06.2025

Trial locations

CART84 is a type of cell therapy where a patient’s own immune cells (T-cells) are modified in a laboratory to recognize and fight cancer cells. This therapy is specifically designed to target cells in acute myeloid leukemia (AML) and acute lymphoblastic T leukemia (T-ALL). The modified T-cells are given back to the patient through an infusion to help their immune system fight the cancer.

Acute Lymphoblastic T Leukemia (T-ALL) – A blood cancer that develops when abnormal T lymphocytes (a type of white blood cell) begin multiplying uncontrollably in the bone marrow. These abnormal cells crowd out healthy blood cells and can spread to other parts of the body. The disease progresses rapidly without intervention, affecting the body’s ability to fight infections and maintain normal blood functions. This condition primarily affects the blood and bone marrow, causing symptoms such as fatigue, frequent infections, and easy bruising.

Acute Myeloid Leukemia (AML) – A type of blood and bone marrow cancer where the body produces abnormal myeloid cells, which are precursors to various types of blood cells. These immature cells accumulate in the bone marrow and interfere with the production of normal blood cells. The disease develops quickly, with abnormal cells rapidly replacing healthy blood-forming cells. As the condition progresses, it affects the body’s ability to produce normal white blood cells, red blood cells, and platelets.

Trial ID:
2024-519966-31-00
Protocol code:
GYA-CART84-AL-001
Trial Phase:
Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

  • Phase 1/2 Study of LB-208 in Adults with Relapsed or Refractory Acute Myeloid Leukaemia and High‑Risk Myelodysplastic Syndrome

    Recruiting

    1 1 1
    Spain

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7